en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank


2/2007
vol. 45
 
Share:
Share:
abstract:

Calcinosis in rheumatic diseases

Anna Rychlewska-Hańczewska
,
Mariusz Puszczewicz

Reumatologia 2007; 45, 2:97-101
Online publish date: 2007/04/25
View full text Get citation
 
Clacinosis occurs in damaged or devitalized tissues in the presence of normal calcium/phosphorus metabolism. It is often noted in the subcutaneous tissues in the course of connective tissues diseases – primarily systemic lupus erythematosus systemicus, sclerodermia and dermatomyositis – and may involve a relatively localized area or be widespread. The aim of the study was to discuss the classification, pathogenesis, clinical features and treatment of calcinosis in rheumatic diseases. The calcinotic accumulations may lead secondarily to muscle atrophy, join contractures and skin ulceration complicated by recurrent episodes of local inflammation and infection. Warfarin, colchicines, probenecid, bisphosphonates, diltiazem, minocycline, aluminium hydroxide, salicylate, surgical extirpation and carbon dioxide laser therapies have been used in the treatment of calcinosis. However, that kind of medication has not convincingly prevented or reduced calcinosis.
keywords:

calcinosis, lupus erythematosus systemicus, sclerodermia, dermatomyositis




Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.